Listing

• Advised Guizhou Zhenhua Fengguang Semiconductor Co., Ltd. (688439.SH) on its IPO and STAR Market listing

• Advised Beijing Tongyi Zhongxin Materials Technology Co., Ltd. (688722.SH) on its IPO and STAR Market listing

• Advised Aojing Medical Technology Co., Ltd. (688613.SH) on its IPO and STAR Market listing

• Advised Hengyu Xintong Aviation Equipment (Beijing) Co., Ltd. (300965.SZ) on its IPO and ChiNext listing

• Advised Beijing Quanshi Tiandi Online Network Information Co., Ltd. (002995.SZ) on its IPO and main board listing

Ms. Li also participated in the initial public offering of Shandong Publishing&Media Co., Ltd. (601019.SH) and its listing on the Main Board of the Shanghai Stock Exchange, Shaanxi Coal Industry Company Limited (601225.SH) and its listing on the Main Board of the Shanghai Stock Exchange, Jinduicheng Molybdenum Company Limited (601958.SH), and other domestic IPOs a number of companies.

M&A, Refinancing, and Restructuring of Listed Companies

• Advised China Petroleum (601857.SH) on the restructuring of its domestic pipeline business and its investment in national pipeline projects

• Advised Beijing Tongyi Zhongxin Materials Technology Co., Ltd. (688722.SH) on its acquiring control of X-FIPER New Material Co., Ltd.

• Advised Beijing Tongyi Zhongxin Materials Technology Co., Ltd. (688722.SH) on its acquiring control of Yancheng Youhebo New Materials Co., Ltd.

• Advised Cisco Rui (688053.SH) on its acquiring control of Shaanxi Haice Electronics Technology Service Co., Ltd.

• Advised China Nuclear Power (601985.SH) on its public offering of convertible bonds

• Advised Baoti Group (600456.SH) on its public offering of corporate bonds

• Advised Dagg Road Machinery (300103.SZ) on its major asset restructuring and related transaction

• Advised China Railway (601390.SH) on its non-public offering

• Advised Jinyu Group (601992.SH) on its acquiring Tangshan Jidong Development Co., Ltd., and indirect acquisition of Tangshan Jidong Cement Co., Ltd. (000401.SZ)

• Advised Sinopec (600028.SH) on its public offering of convertible bonds and restructuring of its overseas subsidiary

• Advised Changling Co., Ltd. (000561.SZ) on its material asset disposal and purchase of assets by issuing shares

• Advised Shaanxi Guotou (000563.SZ) on its material asset disposal and related transactions, involving restructuring and refinancing of a number of listed companies

• Advised Hong Kong Cheung Kong Industries and Hutchison Whampoa on their merger, restructuring, split, and Hong Kong listing

NEEQ Listing/Beijing Stock Exchange

• Advised Jiangsu Feiyu Pharmaceutical Technology Co., Ltd. (874410) on its NEEQ listing and getting included in NEEQ innovation layer

• Advised Beijing Huateng New Material Co., Ltd. (873721) on its NEEQ listing and getting included in NEEQ innovation layer

• Advised Shenzhen Huoli Tianhui Technology Co., Ltd. (871860) on its NEEQ listing

• Advised Qingdao Yeecare Science And Technology Co., Ltd. (837667) on its NEEQ listing

• Advised Henan Liquor Easy Commercial Corporation (838883) on its NEEQ listing and subsequent private placement

• Advised Beijing Yingguan Dental Technology Co., Ltd. (838197) on its NEEQ listing

• Advised SOARLE Intelligence Technology Co., Ltd. (430758) on its NEEQ listing

Private Equity Investment 

Ms. Li has acted for a number of domestic private equity funds and fund management companies concerning their investment. Notable clients include National Military and Civilian Integration Industry Investment Fund Co., Ltd., Guotou Chuanghe National Emerging Industry Venture Capital (LP), Military Civilian Integration Development Industry Investment Fund (LP), Shanghai Civil-Military Integration Industry Equity Investment Fund Partnership (LP), Hubei Province Integrated Development Industry Investment Fund Partnership Enterprise (LP), Hangzhou Chuanghe Selected Entrepreneurial Investment Partnership (LP), Jiangxi Jinggangshan Beiqi Investment Management Co., Ltd., Tianjin Wutong Tree Private Equity Fund Management Co., Ltd., fu nds owned by China Aerospace Science and Industry Corporation (CASIC), and Tsing Song Capital.

Medical/Biotech/Pharmaceutical/Life Sciences Industry

• Advised Jiangsu Trulive Medtech Co., Ltd. (structural heart disease) on its equity investment

• Advised ArtSurgical Medical Technology (Suzhou) Co., Ltd. (surgical robotics) on its equity investment

• Advised Shanghai MicroPort CardioFlow MedTech Ltd. (research, development, production, and sales of VitaFlow transcatheter aortic valve and delivery systems) on its Series B equity investment

• Advised Shanghai Yinosi Biotechnology Co., Ltd. (preclinical safety assessment research services for pharmaceutical institutions worldwide) on its equity investment

• Advised Shanghai Ailis Pharmaceutical Technology Co., Ltd. (innovative drug development and production for hypertension, oncology, diabetes, etc.) on its equity investment

• Advised Shanghai Aohua Endoscopy Co., Ltd. (medical endoscopes and related products) on its equity investment 

• Advised Anlong Gene Pharmaceutical Technology Co., Ltd. (gene therapy) on its equity investment

• Advised Beijing G-Eno Gene Technology Co., Ltd. (genetic testing) on its equity investment

• Advised Shanghai Huihe Medical Technology Co., Ltd. (tricuspid valve repair products for cardiac applications) on its equity investment

• Advised Chasen Medical Devices (Tianjin) Co., Ltd. (orthopedic implant products) on its equity investment

• Advised Wuxi Shangwo Medical Electronics Co., Ltd. (breath-based molecular diagnostic biosensor medical electronic products) on its equity investment

• Advised Cangzhou Four Stars Glass Co., Ltd. (medical neutral borosilicate glass tubing, oral glass bottles, and anatomical bottles) on its equity investment

• Advised Yichang Dongyangguang Pharmaceutical Co., Ltd. (active pharmaceutical ingredients) and Ruyuan Dongyangguang Pharmaceutical Co., Ltd. (active pharmaceutical ingredients) on its equity investment

• Advised Beijing Kandehong Trading Development Co., Ltd. and Beijing Yingchuangbaili Technology Development Co., Ltd. (sales of large-scale medical equipment in the radiological field, medical consumables, rental of medical equipment, and equipment management and maintenance services) on its equity investment

Military and Defense Industry Capital Operations and Financing

• Advised China Changzheng Rocket Co., Ltd. (space launch services and payload system design) on its equity investment

• Advised Beijing Future Navigation Technology Co., Ltd. (Beidou satellite low-orbit navigation enhancement system and satellite constellation) on its equity investment

• Advised Beijing Maniu Technology Co., Ltd. (big data analysis and applications in public safety) on its equity investment

• Advised Chengdu Rongxing Technology Co., Ltd. (radio signal monitoring and information processing) on its equity investment

• Advised Xingzhan Measurement & Control Technology Co., Ltd. (satellite communication antennas for vehicles, ships, and aircraft) on its equity investment

• Advised Topwiz Electronics Technology (Shanghai) Co., Ltd. (chip research and development for digital and RF chips) on its equity investment

• Advised Changchun Tongshi Optoelectronic Technology Co., Ltd. (optoelectronic systems including dynamic base imaging, axis stabilization, and target aiming) on its equity investment

• Advised Shenzhen Kexin Technology Co., Ltd. (electronic information equipment for communication and meteorological detection fields) on its equity investment

• Advised on the subscription of the non-publicly issued shares in Zhongtung High-Tech Materials Co., Ltd. (development of rare metals and deep processing products)

• Advised on the subscription of the non-publicly issued shares in Shanghai Sinan Satellite Navigation Technology Co., Ltd. (the first domestic enterprise fully mastering core technology for high-precision Beidou/GNSS receiver modules)

ESOP

Ms. Li has advised clients on the design and development of employee equity incentive programs and contributed to their successful implementation. Her mandates in this area include employee restricted stock incentives after its IPO for Aojing Medical (688613.SH); proposed pre-IPO employee equity incentives for state-owned enterprises including Tongyi Zhongxin (688722.SH), Financial Street Properties (01502.HK), Morningcore Holding Co., Ltd., and Shaanxi Huajing Micro-Electronics Stock Co., Ltd.; pre-IPO employee incentives for Aojing Medical (688613.SH), Quanshi Tiandi Online Network Information (002995.SZ), Huajing Microelectronics, and Vivolight, and Shaanxi Huajing Micro-Electronics Stock Co., Ltd.; as well as equity incentives and ESOPs for dozens of other (listed) companies.

Retainer-based Services and Compliance

Ms. Li served and is serving as retainer-based counsel and compliance counsel for many companies, including:

• Zhenhua Fengguang (688439.SH)

• Aojing Medical (688613.SH)

• Tongyi Zhongxin (688722.SH)

• Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ)

• Ruijie Networks Co., Ltd. (301165.SZ)

• Shaanxi Huajing Micro-Electronics Stock Co., Ltd.

• Shenzhen Vivolight Medical Device & Technology Co., Ltd.

• Jiangxi Tianyi Aviation Equipment Co. Ltd.

• Beijing Shendao Technology Co., Ltd.

• ArtSurgical Medical Technology (Suzhou) Co., Ltd.